METTL14 and hepatocellular carcinoma: Concurrently, METTL14 deficiency activates S100A4+ Macrophages through the myeloid differentiation primary response 88 (MyD88)/NF-κB signaling, ultimately driving hepatocellular carcinoma progression [122].